324 related articles for article (PubMed ID: 18780832)
21. Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.
Pillon M; Aricò M; Basso G; Locatelli F; Citterio M; Micalizzi C; Testi AM; Barisone E; Nardi M; Lombardi A; Rondelli R; Rosolen A;
Pediatr Blood Cancer; 2011 Apr; 56(4):544-50. PubMed ID: 21298738
[TBL] [Abstract][Full Text] [Related]
22. Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy.
Alduailej H; Kanfar S; Bakhit K; Raslan H; Alsaber A; Bashawri L; Aldayel A; Alanezi K
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e560-e568. PubMed ID: 32600932
[TBL] [Abstract][Full Text] [Related]
23. Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Corbacioglu S; Eber S; Gungor T; Hummerjohann J; Niggli F
J Pediatr Hematol Oncol; 2003 Apr; 25(4):327-9. PubMed ID: 12679650
[TBL] [Abstract][Full Text] [Related]
24. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy.
van Lochem EG; Wiegers YM; van den Beemd R; Hählen K; van Dongen JJ; Hooijkaas H
Leukemia; 2000 Apr; 14(4):688-95. PubMed ID: 10764156
[TBL] [Abstract][Full Text] [Related]
25. Half-and-half nails in a pediatric patient after chemotherapy.
Afsar FS; Ozek G; Vergin C
Cutan Ocul Toxicol; 2015; 34(4):350-1. PubMed ID: 25597374
[TBL] [Abstract][Full Text] [Related]
26. Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.
Chevallier P; Pigneux A; Robillard N; Ayari S; Guillaume T; Delaunay J; Eveillard M; Dumas PY; Lippert E; Mohty M; Leguay T
Leuk Res; 2012 Mar; 36(3):311-5. PubMed ID: 22172463
[TBL] [Abstract][Full Text] [Related]
27. Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.
Ferreri AJ; Dognini GP; Verona C; Patriarca C; Doglioni C; Ponzoni M
Haematologica; 2007 Jan; 92(1):e1-2. PubMed ID: 17405748
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
29. High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Reismüller B; Steiner M; Pichler H; Dworzak M; Urban C; Meister B; Schmitt K; Pötschger U; König M; Mann G; Haas OA; Attarbaschi A;
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27804199
[TBL] [Abstract][Full Text] [Related]
30. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
Papayannidis C; Derenzini E; Iacobucci I; Curti A; Paolini S; Cilloni D; Baccarani M; Martinelli G
Am J Hematol; 2009 Dec; 84(12):849-50. PubMed ID: 19844989
[No Abstract] [Full Text] [Related]
31. [Expression of CD20 in B-cell precursor acute lymphoblastic leukemia and its correlation with clinical outcomes].
Chen XX; Yuan LX; Zhang G; Wan CM; Huo WY; Tang X; Ai Y; Wan Z; Zhu YP; Gao J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):658-63. PubMed ID: 25286695
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
33. Infusion of anti-CD10 monoclonal antibody (J5) following ablative chemotherapy in a patient with refractory pre-B acute lymphoblastic leukemia.
Ruiz-Argüelles GJ; Ruiz-Argüelles A; Lobato-Mendizábal E; Presno-Bernal M; Alvarez-Amaya C
Rev Invest Clin; 1991; 43(3):259-63. PubMed ID: 1840161
[TBL] [Abstract][Full Text] [Related]
34. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group.
Dworzak MN; Gaipa G; Schumich A; Maglia O; Ratei R; Veltroni M; Husak Z; Basso G; Karawajew L; Gadner H; Biondi A
Cytometry B Clin Cytom; 2010 May; 78(3):147-53. PubMed ID: 20201055
[TBL] [Abstract][Full Text] [Related]
35. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
Claviez A; Eckert C; Seeger K; Schrauder A; Schrappe M; Henze G; von Stackelberg A
Haematologica; 2006 Feb; 91(2):272-3. PubMed ID: 16461321
[TBL] [Abstract][Full Text] [Related]
36. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
[TBL] [Abstract][Full Text] [Related]
37. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
38. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia.
Hoshitsuki K; Zhou Y; Miller AM; Choi JK; Swanson HD; Bhakta NH; Jeha S; Karol SE; Ribeiro RC; Rubnitz JE; Mullighan CG; Cheng C; Yang JJ; Relling MV; Pui CH; Inaba H
Leukemia; 2023 Sep; 37(9):1782-1791. PubMed ID: 37543655
[TBL] [Abstract][Full Text] [Related]
39. Association of three factors (ABCB1 gene expression, steroid response, early response at day + 8) on the response to induction in patients with acute lymphoblastic leukemia.
Ramos-Peñafiel C; Olarte-Carrillo I; Maldonado RC; de la Cruz Rosas A; Collazo-Jaloma J; Martínez-Tovar A
Ann Hematol; 2020 Nov; 99(11):2629-2637. PubMed ID: 32980890
[TBL] [Abstract][Full Text] [Related]
40. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
